Competitions like ISEF are the staging grounds for the next generation of engineers and scientists, and they must preserved.

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...

Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also ...

Humankind Investments increased its stake in Regeneron Pharmaceuticals by 62.3%, showing rising investor interest despite the ...

Regeneron Pharmaceuticals Up Nearly 7%, On Pace For Largest Percent Increase Since September 2022 — Data Talk Regeneron Pharmaceuticals, Inc. (REGN) is currently at $568.11, up $40.33 or 7.64% --On ...

The $40 billion investment will be spread across various R&D and manufacturing areas over the next five years.

The company said the discontinuation was due to several reasons,” Reuters news service reported, “including limited interest ...

Salusiwe Mxayiya from Luhlaza High School in Khayelitsha, alongside other young innovators, proudly represents South Africa ...

Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

New Paltz High School senior Joseph Birnbaum was named a scholar in the Regeneron Science Talent Search (STS) for his ...